Company: NCEL
Filing Date: 2025-03-03
Form Type: F-4/A
Source: 0001213900-25-018981
Chunk: 330

Company: NewcelX Ltd.
Filing Date: 2025-03-03
Form: F-4/A
Chunk 330
---
. Ariel Revel has served since January 2020 as Kadimastem’s Medical Affairs Director. From January 2024, Prof. Revel has also been a Medical Doctor at Maccabi Health Care Service. Since April 2017, he has also been a professor of medicine at Tel Aviv University. He was also a Visiting Professor at Oxford University in the UK from October 2008 to October 2009 and a Visiting Professor at Stanford University in California from October 2015 to October 2016. Additionally, from April of 2017 and until April of 2024 he served in Assaf Harofeh Medical Center. From April 2017 until April 2021, he served as a professor at Assaf Harofeh Medical Center. He began his medical career in August of 2000 as the head of Fertility Preservation Services at Hadassah Medical Center until May of 2017. Professor Revel received his Ph.D. from Tel -AvivUniversity, and an M.D. degree from the Hebrew University of Jerusalem. Eric Konofal, Chief Scientific Officer Eric Konofal, MD, Ph.D. was appointed as our Interim Chief Scientific Officer in February 2021. Dr. Konofal is an IP expert and co -founderof NLS Pharmaceutics Ltd. Dr. Konofal has been active for more than 27 years in the field of sleep research, including narcolepsy and hypersomnia, as a clinician, scientific researcher, and drug hunter. From 2006 to date, Dr. Konofal serves as a senior medical consultant for the Pediatric Sleep Disorders Center and the Child and Adolescent Psychiatry Department at Robert Debré Hospital (APHP). Dr. Konofal received his medical doctorate and Ph.D. from the University Pierre — Marie Curie, Paris/France. Olivier Samuel, Director Mr. Samuel has served as director of Kadimastem since January 2020. Mr. Samuel brings over 25 years of experience in product sales in the medical space. From March 2021 and until today, Mr. Samuel has served as a professional mediator is a self -employedProfessional Mediator. From January 1997 until December 2019, Mr. Samuel was the CEO of Adomsante in France. Mr. Samuel has a master’s in business administration and management from Emlyon Business School and the Lille School of Health Engineers. 181 Eran Iohan, Independent Director Mr. Eran I